Skip to main content

Advertisement

Log in

The role of 18F-FLT in cancer imaging: does it really reflect proliferation?

  • Editorial commentary
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

The Original Article was published on 25 October 2007

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Been LB, Suurmeijer AJH, Cobben DCP, Jager PL, Hoekstra HJ, Elsinga PH. (18F)FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging 2004;31:1659–72.

    Article  PubMed  Google Scholar 

  2. Christman D, Crawford EJ, Friedkin M, Wolf AP. Detection of DNA synthesis in intact organisms with positron-emitting (methyl-11C)thymidine. Proc Natl Acad Sci U S A 1972;69:988–92.

    Article  PubMed  CAS  Google Scholar 

  3. Visvikis D, Francis D, Mulligan R, Costa DC, Croasdale I, Luthra SK, et al. Comparison of methodologies for the in vivo assessment of 18FLT utilisation in colorectal cancer. Eur J Nucl Med Mol Imaging 2004;31:169–78.

    Article  PubMed  CAS  Google Scholar 

  4. Shields AF. PET Imaging with 8F-FDG and thymidine analogs: promise and pitfalls. J Nucl Med 2003;44:1432–4.

    PubMed  CAS  Google Scholar 

  5. Krohn KA, Mankoff DA, Muzi M, Link JM, Spence AM. True tracers: comparing FDG with glucose and FLT with thymidine. Nucl Med Biol 2005;32:663–71.

    Article  PubMed  CAS  Google Scholar 

  6. Belt JA, Marina NM, Phelps DA, Crawford CR. Nucleoside transport in normal and neoplastic cells. Adv Enzyme Regul 1993;33:235–52.

    Article  PubMed  CAS  Google Scholar 

  7. Strauss LG, Klippel S, Pan L, Schönleben K, Haberkorn U, Dimitrakopoulou-Strauss A. Assessment of quantitative FDG PET data in primary colorectal tumours: which parameters are important with respect to tumour detection? Eur J Nucl Med Mol Imaging 2007;34:868–77.

    Article  PubMed  Google Scholar 

  8. Munch-Petersen B, Tyrsted G, Cloos L. Reversible ATP-dependent transition between two forms of human cytosolic thymidine kinase with different enzymatic properties. J Biol Chem 1993;268:15621–5.

    PubMed  CAS  Google Scholar 

  9. Barthel H, Cleij MC, Collingridge DR, Hutchinson C, Osman S, He Q, et al. 3′-deoxy-3′-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 2003;63:3791–8.

    PubMed  CAS  Google Scholar 

  10. Lu L, Samuelsson L, Bergström M, Sato K, Fasth K-J, Langström B. Rat studies comparing 11C-FMAU, 18F-FLT, and 76Br-BFU as proliferation markers. J Nucl Med 2002;43:1688–98.

    PubMed  CAS  Google Scholar 

  11. Quon A, Chang ST, Kamaya A, Dick DW, Loo BW Jr, Gambhir SS, et al. Pilot evaluation of 18F-fluorothymidine (FLT) PET/CT scanning for primary pancreatic cancer. Eur J Nucl Med Mol Imaging 2007; in press.

  12. Seitz U, Wagner M, Neumaier, et al. Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3′-[(18)F]fluoro-3′-deoxythymidine ([(18)F]FLT) in pancreatic cancer cell lines. Eur J Nucl Med Mol Imaging 2002;9:1174–81.

    Article  Google Scholar 

  13. Choi SJ, Kim JS, Kim JH, Oh SJ, Lee JG, Kim CJ, et al. 18F]3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imaging 2005;32:653–9.

    Article  PubMed  Google Scholar 

  14. Cobben DCP, Elsinga PH, Suurmeijer AJH, Vaalburg W, Maas B, Jager PL, et al. Detection and grading of soft tissue sarcomas of the extremities with (18)F-3′-fluoro-3′-deoxy-l-thymidine. Clin Cancer Res 2004;10:1685–90.

    Article  PubMed  CAS  Google Scholar 

  15. Buchmann I, Neumaier B, Schreckenberger M, Reske S. 18F]3′-deoxy-3′-fluorothymidine-PET in NHL patients: whole-body biodistribution and imaging of lymphoma manifestations—a pilot study. Cancer Biother Radiopharm 2004;19:436–42.

    PubMed  CAS  Google Scholar 

  16. Dittman H, Dohmen BM, Paulsen F, Eichhorn K, Eschmann SM, Horger M, et al. (18F)FLT PET for diagnosis and staging of thoracic tumors. Eur J Nucl Med Mol Imaging 2003;30:1407–12.

    Article  Google Scholar 

  17. Buck AK, Hetzel M, Schirrmeister H, Halter G, Möller P, Kratochwill C, et al. Clinical relevance of imaging proliferative activity in lung nodules. Eur J Nucl Med Mol Imaging 2005;32:525–33.

    Article  PubMed  Google Scholar 

  18. Been LB, Elsinga PH, deVries J, Cobben DCP, Jager PL, et al. Positron emission tomography in patients with breast cancer using (18)F-3′-deoxy-3′-fluoro-l-thymidine ((18)F-FLT)—a pilot study. Eur J Surg Oncol 2006;32:39–43.

    Article  PubMed  CAS  Google Scholar 

  19. Francis DL, Visvikis D, Costa DC, Arulampalam TH, Townsend C, Luthra SK, et al. Potential impact of [18F]3′-deoxy-3′-fluorothymidine versus [18F]fluoro-2-deoxy-d-glucose in positron emission tomography for colorectal cancer. Eur J Nucl Med Mol Imaging 2003;30:988–94.

    Article  PubMed  CAS  Google Scholar 

  20. Leyton J, Latigo JR, Perumal M, Dhaliwal H, He Q, Aboagye EO. Early detection of tumor response to chemotherapy by 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res 2005;65:4202–10.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Antonia Dimitrakopoulou-Strauss.

Additional information

This Editorial commentary refers to the article http://dx.doi.org/10.1007/s00259-007-0630-z.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dimitrakopoulou-Strauss, A., Strauss, L.G. The role of 18F-FLT in cancer imaging: does it really reflect proliferation?. Eur J Nucl Med Mol Imaging 35, 523–526 (2008). https://doi.org/10.1007/s00259-007-0679-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-007-0679-8

Navigation